Page 146 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology CRCI factors in breast cancer

Table 1. (Continued)
Characteristic Number (n) Percentage
TNM stage
I 92 24.21
II 168 44.21
III 83 21.84
IV 37 9.74
Complication
Yes 59 15.53
No 321 84.47
Living situation
Living alone 46 12.11
Not living alone 334 87.89
Diabetes
Yes 69 18.16
No 311 81.84
BMI (kg/m )
2
<18.5 98 25.79
18.5 – 24 121 31.84
24 – 28 105 27.63
≥28 56 14.74
Abbreviation: BMI: Body mass index.

Table 2. Comparison of cognitive function scores of breast cancer patients before chemotherapy and 3 months after
chemotherapy
Items Before chemotherapy Three months after chemotherapy t p
Perceived cognitive impairment 62.86±8.18 58.89±8.19 −2.365 0.014*
Comments from others 13.07±2.08 12.95±2.10 −0.112 0.901
Perceived cognitive abilities 26.95±6.66 18.71±7.01 −8.235 0.001**
Impact on QoL 11.79±1.85 11.68±1.74 −0.16 0.863
Total FACT-Cog score 116.71±11.78 104.76±22.18 −4.376 0.001**
Notes: *p<0.05, **p<0.01.
Abbreviations: FACT-Cog: Functional Assessment of Cancer Therapy-Cognitive Function scale; QoL: Quality of life.

Table 3. Analysis of anxiety and depression scores in breast cancer patients undergoing chemotherapy
Items n (%) Mean±SD
Not present Mild Moderate Severe
Anxiety 195 (51.32) 114 (30) 60 (15.79) 11 (2.89) 16.18±3.77
Depression 196 (51.58) 120 (31.58) 55 (14.47) 9 (2.37) 17.39±3.95
Abbreviation: SD: Standard deviation.

3.4. Univariate analysis of factors affecting cognitive patients. These factors include educational level, method
function in breast cancer patients of medical payment, disease stage, and the presence of
The analysis results suggest several potential factors complications, all of which were statistically significant
influencing cognitive function among breast cancer (p<0.05). For a detailed breakdown, please refer to Table 5.

Volume 9 Issue 3 (2025) 138 doi: 10.36922/EJMO025130073